BR112017023171A2 - adenovírus oncolítico que codifica proteína b7 - Google Patents

adenovírus oncolítico que codifica proteína b7

Info

Publication number
BR112017023171A2
BR112017023171A2 BR112017023171-9A BR112017023171A BR112017023171A2 BR 112017023171 A2 BR112017023171 A2 BR 112017023171A2 BR 112017023171 A BR112017023171 A BR 112017023171A BR 112017023171 A2 BR112017023171 A2 BR 112017023171A2
Authority
BR
Brazil
Prior art keywords
oncolytic adenovirus
virus
encoding protein
adenovirus encoding
compositions
Prior art date
Application number
BR112017023171-9A
Other languages
English (en)
Inventor
Robert Champion Brian
Claire Noel Bromley Alice
Original Assignee
Psioxus Therapeutics Limited
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB1507419.8A external-priority patent/GB201507419D0/en
Priority claimed from GBGB1516936.0A external-priority patent/GB201516936D0/en
Priority claimed from GBGB1522013.0A external-priority patent/GB201522013D0/en
Application filed by Psioxus Therapeutics Limited filed Critical Psioxus Therapeutics Limited
Priority to BR122018004815A priority Critical patent/BR122018004815A2/pt
Publication of BR112017023171A2 publication Critical patent/BR112017023171A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/76—Viruses; Subviral particles; Bacteriophages
    • A61K35/761—Adenovirus
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C12N15/861—Adenoviral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/521—Chemokines
    • C07K14/523—Beta-chemokines, e.g. RANTES, I-309/TCA-3, MIP-1alpha, MIP-1beta/ACT-2/LD78/SCIF, MCP-1/MCAF, MCP-2, MCP-3, LDCF-1, LDCF-2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/555—Interferons [IFN]
    • C07K14/56—IFN-alpha
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70532—B7 molecules, e.g. CD80, CD86
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/71—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2809—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/03—Fusion polypeptide containing a localisation/targetting motif containing a transmembrane segment
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
    • C07K2319/74—Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10321—Viruses as such, e.g. new isolates, mutants or their genomic sequences
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10332—Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10341—Use of virus, viral particle or viral elements as a vector
    • C12N2710/10343—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10371—Demonstrated in vivo effect

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Virology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Microbiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Cell Biology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

a presente revelação fornece um adenovírus oncolítico competente para replicação com seletividade para células cancerígenas, em que o adenovírus compreende um transgene sob o controle de um promotor endógeno ao vírus, em que o transgene compreende uma sequência de dna que codifica uma proteína b7 ou um fragmento ativo da mesma, composições que compreendem o mesmo, métodos de geração dos vírus, e uso do vírus e composições em tratamento, particularmente, no tratamento de câncer.
BR112017023171-9A 2015-04-30 2016-04-29 adenovírus oncolítico que codifica proteína b7 BR112017023171A2 (pt)

Priority Applications (1)

Application Number Priority Date Filing Date Title
BR122018004815A BR122018004815A2 (pt) 2015-04-30 2016-04-29 adenovírus oncolítico que codifica proteína b7

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
GB1507419.8 2015-04-30
GBGB1507419.8A GB201507419D0 (en) 2015-04-30 2015-04-30 Virus
GB1516936.0 2015-09-24
GBGB1516936.0A GB201516936D0 (en) 2015-09-24 2015-09-24 Virus
GB1522013.0 2015-12-14
GBGB1522013.0A GB201522013D0 (en) 2015-12-14 2015-12-14 Virus
PCT/EP2016/059609 WO2016174200A1 (en) 2015-04-30 2016-04-29 Oncolytic adenovirus encoding a b7 protein

Publications (1)

Publication Number Publication Date
BR112017023171A2 true BR112017023171A2 (pt) 2018-07-17

Family

ID=56008588

Family Applications (2)

Application Number Title Priority Date Filing Date
BR122018004815A BR122018004815A2 (pt) 2015-04-30 2016-04-29 adenovírus oncolítico que codifica proteína b7
BR112017023171-9A BR112017023171A2 (pt) 2015-04-30 2016-04-29 adenovírus oncolítico que codifica proteína b7

Family Applications Before (1)

Application Number Title Priority Date Filing Date
BR122018004815A BR122018004815A2 (pt) 2015-04-30 2016-04-29 adenovírus oncolítico que codifica proteína b7

Country Status (31)

Country Link
US (6) US11000559B2 (pt)
EP (2) EP3391892A1 (pt)
JP (3) JP6931229B2 (pt)
KR (3) KR20180118249A (pt)
CN (2) CN107690479B (pt)
AU (3) AU2016256582B2 (pt)
BR (2) BR122018004815A2 (pt)
CA (1) CA2984038C (pt)
CL (2) CL2017002731A1 (pt)
CO (1) CO2017010831A2 (pt)
CY (1) CY1122833T1 (pt)
DK (1) DK3288573T3 (pt)
EA (1) EA037611B1 (pt)
ES (1) ES2780366T3 (pt)
HK (1) HK1249009A1 (pt)
HR (1) HRP20200439T1 (pt)
HU (1) HUE048320T2 (pt)
IL (3) IL284375B (pt)
LT (1) LT3288573T (pt)
MX (1) MX2017013684A (pt)
MY (1) MY183703A (pt)
PE (2) PE20181140A1 (pt)
PH (1) PH12017501942A1 (pt)
PL (1) PL3288573T3 (pt)
PT (1) PT3288573T (pt)
RS (1) RS60105B1 (pt)
SA (2) SA520412637B1 (pt)
SG (3) SG10201901482XA (pt)
SI (1) SI3288573T1 (pt)
WO (1) WO2016174200A1 (pt)
ZA (1) ZA201801589B (pt)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201322851D0 (en) 2013-12-23 2014-02-12 Psioxus Therapeutics Ltd Method
AU2014338864C1 (en) 2013-10-25 2020-07-16 Akamis Bio Limited Oncolytic adenoviruses armed with heterologous genes
GB201406608D0 (en) 2014-04-12 2014-05-28 Psioxus Therapeutics Ltd Virus
US11000559B2 (en) 2015-04-30 2021-05-11 Psioxus Therapeutics Limited Oncolytic adenovirus encoding a B7 protein
TW201722985A (zh) 2015-11-02 2017-07-01 戊瑞治療有限公司 Cd80胞外域多肽及其用於癌症治療
MX2018007249A (es) * 2015-12-17 2019-05-16 Psioxus Therapeutics Ltd Adenovirus del grupo b que codifica un anticuerpo contra el complejo tcr o fragmento de este.
DK3436591T3 (da) * 2016-03-31 2023-03-20 The European Molecular Biology Laboratory Adenovirale coat-protein-afledte transportvehikler
GB201713765D0 (en) 2017-08-28 2017-10-11 Psioxus Therapeutics Ltd Modified adenovirus
EP3507304B1 (en) 2016-09-02 2024-04-03 Lentigen Technology, Inc. Compositions and methods for treating cancer with duocars
EP3518947B1 (en) * 2016-09-27 2023-07-05 Sator Therapeutics LLC Optimized oncolytic viruses and uses thereof
WO2018083258A1 (en) * 2016-11-03 2018-05-11 Psioxus Therapeutics Limited Oncolytic adenovirus encoding at least three transgenes
WO2018083259A1 (en) * 2016-11-03 2018-05-11 Psioxus Therapeutics Limited Oncolytic adenovirus encoding transgenes
WO2018083257A1 (en) * 2016-11-03 2018-05-11 Psioxus Therapeutics Limited Oncolytic adenovirus encoding transgenes
JP2020514324A (ja) * 2017-02-03 2020-05-21 ユニバーシティ オブ ピッツバーグ −オブ ザ コモンウェルス システム オブ ハイヤー エデュケイション 腫瘍溶解性ウイルス療法
JP2020517913A (ja) 2017-04-28 2020-06-18 ファイブ プライム セラピューティクス， インコーポレイテッド Ｃｄ８０細胞外ドメインポリペプチドによる治療方法
IL270876B1 (en) * 2017-05-25 2024-02-01 Univ Central Florida Res Found Inc Novel oncolytic viruses to induce tumor cell killing by natural killer cells
CA3064863A1 (en) * 2017-05-26 2018-11-29 Epicentrx, Inc. Recombinant adenoviruses carrying transgenes
ES2952601T3 (es) 2017-06-01 2023-11-02 Akamis Bio Ltd Virus oncolítico y método
WO2019147921A1 (en) * 2018-01-26 2019-08-01 Nantcell, Inc. Rapid verification of virus particle production for a personalized vaccine
GB201801614D0 (en) * 2018-01-31 2018-03-14 Psioxus Therapeutics Ltd Formulation
US20210040167A1 (en) * 2018-03-05 2021-02-11 The Schepens Eye Research Institute, Inc. Engineered vegf variants for retinal neuroprotection, promotion of axon growth and axon regeneration
KR20200136972A (ko) * 2018-03-30 2020-12-08 도모키 도도 종창 발생 억제형 종양 용해성 바이러스
WO2020052551A1 (en) * 2018-09-10 2020-03-19 Genesail Biotech (Shanghai) Co. Ltd. A modified oncolytic virus, composition and use thereof
EP3725323A1 (en) * 2019-04-17 2020-10-21 Targovax Asa Oncolytic adenoviral vector expressing a member of the b7 family of costimulatory ligands and ada
US11434291B2 (en) 2019-05-14 2022-09-06 Provention Bio, Inc. Methods and compositions for preventing type 1 diabetes
EP3970754A4 (en) * 2019-05-14 2023-08-02 Oncolys BioPharma, Inc. METHOD FOR ADMINISTRATION OF AN ONCOLYTIC VIRUS TO TUMOR TISSUE, AND ADMINISTRATION DEVICE
GB201909081D0 (en) 2019-06-25 2019-08-07 Psioxus Therapeutics Ltd Method
GB202102049D0 (en) * 2021-02-13 2021-03-31 Psioxus Therapeutics Ltd Viruses
WO2023180527A1 (en) * 2022-03-25 2023-09-28 Universität Zürich Adenoviral mediated targeting of activated immune cells

Family Cites Families (77)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3405241A1 (de) * 1984-02-15 1985-08-29 Bayer Ag, 5090 Leverkusen 1-/4-(benzothia- oder -oxazol-2-ylthio- oder -2-yloxy) phenyl/-1,3,5-triazin-2,4,6-(1h,3h,5h)-trione, verfahren zu ihrer herstellung und ihre verwendung als arzneimittel
KR920008907B1 (ko) * 1989-11-28 1992-10-10 삼성전자 주식회사 파우어 온/오프시 화면 크기 제어회로
US5358866A (en) 1991-07-03 1994-10-25 The United States Of America As Represented By The Department Of Health And Human Services Cytosine deaminase negative selection system for gene transfer techniques and therapies
US5846945A (en) 1993-02-16 1998-12-08 Onyx Pharmaceuticals, Inc. Cytopathic viruses for therapy and prophylaxis of neoplasia
FR2705361B1 (fr) 1993-05-18 1995-08-04 Centre Nat Rech Scient Vecteurs viraux et utilisation en thérapie génique.
EP0667912B1 (fr) 1993-07-13 2008-07-02 Centelion Vecteurs adenoviraux defectifs et utilisation en therapie genique
US5631236A (en) 1993-08-26 1997-05-20 Baylor College Of Medicine Gene therapy for solid tumors, using a DNA sequence encoding HSV-Tk or VZV-Tk
US5830686A (en) 1994-01-13 1998-11-03 Calydon Tissue-specific enhancer active in prostate
US5677170A (en) 1994-03-02 1997-10-14 The Johns Hopkins University In vitro transposition of artificial transposons
US5877011A (en) 1996-11-20 1999-03-02 Genzyme Corporation Chimeric adenoviral vectors
CN1242051A (zh) 1996-12-31 2000-01-19 昂尼克斯药物公司 用于肿瘤治疗和预防的致细胞病变病毒
ATE374821T1 (de) 1997-02-20 2007-10-15 Univ Johns Hopkins Med Mutationen in atp-abhängigen transpositionsproteinen die die zielortspezifität reduzieren
US20030044384A1 (en) 1997-10-09 2003-03-06 Pro-Virus, Inc. Treatment of neoplasms with viruses
WO2000034494A1 (en) * 1998-12-09 2000-06-15 The Government Of The United States Of America Represented By The Secretary, Department Of Health And Human Services A recombinant vector expressing multiple costimulatory molecules and uses thereof
US6291214B1 (en) 1998-05-11 2001-09-18 Glaxo Wellcome Inc. System for generating recombinant viruses
US20020019051A1 (en) 1998-05-27 2002-02-14 Monika Lusky Chimeric adenoviral vectors
US20030017138A1 (en) 1998-07-08 2003-01-23 Menzo Havenga Chimeric adenoviruses
CN1110553C (zh) 1998-07-15 2003-06-04 杭州赛狮生物技术开发有限公司 基因工程腺病毒及其用途
AU767975B2 (en) * 1998-09-11 2003-11-27 Genvec, Inc. Alternatively targeted adenovirus
DE60045138D1 (de) 1999-05-17 2010-12-02 Crucell Holland Bv Rekombinantes Adenovirus des Ad26-Serotyps
EP1181382B1 (en) 1999-06-01 2005-03-23 The University of Washington Recombinant adenoviral vectors expressing chimeric fiber proteins for cell specific infection and genome integration
US7396679B2 (en) 1999-11-15 2008-07-08 Onyx Pharmaceuticals, Inc. Oncolytic adenovirus
CA2398335C (en) * 2000-01-21 2010-12-07 Biovex Limited Herpes virus strains
US7456009B2 (en) 2000-03-07 2008-11-25 Merck & Co., Inc. Adenovirus formulations
WO2001092549A2 (en) 2000-05-31 2001-12-06 Genvec, Inc. Method and composition for targeting an adenoviral vector
ATE449859T1 (de) 2001-01-04 2009-12-15 Goeran Wadell Virusvektor zur gentherapie
US20050175589A1 (en) * 2001-07-13 2005-08-11 Btg International Limited Anti-neoplastic viral agents
AR039067A1 (es) 2001-11-09 2005-02-09 Pfizer Prod Inc Anticuerpos para cd40
EP1327688A1 (en) 2002-01-14 2003-07-16 Vereniging Voor Christelijk Wetenschappelijk Onderwijs Adenoviruses with enhanced lytic potency
AU2003206815A2 (en) * 2002-02-01 2003-09-02 Transgene S.A. Adenoviral vectors for modulating the cellular activities associated with PODs
US7858367B2 (en) 2002-04-30 2010-12-28 Duke University Viral vectors and methods for producing and using the same
CN1705740B (zh) * 2002-10-15 2013-07-24 佩尔·松内·霍尔姆 具有反向基因表达的腺病毒及其应用
US20040167088A1 (en) 2003-02-25 2004-08-26 Genvec, Inc. Method of using adenoviral vectors with increased persistence in vivo
WO2004087930A1 (en) 2003-03-28 2004-10-14 Saint Louis University Adenovirus replication-competent vectors expressing trail
US20050136035A1 (en) * 2003-06-03 2005-06-23 Derek Ko Cell specific replication-competent viral vectors comprising a self processing peptide cleavage site
US20050036989A1 (en) 2003-07-18 2005-02-17 Onyx Pharmaceuticals, Inc. Subgroup B adenoviral vectors for treating disease
US20050186178A1 (en) * 2003-08-28 2005-08-25 Ennist David L. Oncolytic adenoviral vectors encoding GM-CSF
WO2005086922A2 (en) 2004-03-10 2005-09-22 Board Of Regents, University Of Texas System Oncolytic adenovirus armed with therapeutic genes
US20080292592A1 (en) 2004-04-30 2008-11-27 Sunil Chada Oncolytic Adenovirus Armed with Therapeutic Genes
CA2567094C (en) * 2004-05-26 2014-11-25 Schering Aktiengesellschaft Chimeric adenoviruses for use in cancer treatment
CN100361710C (zh) 2004-06-07 2008-01-16 成都康弘生物科技有限公司 肿瘤细胞专一表达免疫调节因子gm-csf的溶瘤性腺病毒重组体的构建及其应用
US20060292682A1 (en) * 2004-07-22 2006-12-28 Hawkins Lynda K Addition of transgenes into adenoviral vectors
CN101068933A (zh) * 2004-08-25 2007-11-07 细胞基因系统有限公司 用于肿瘤细胞增强转导的纤维修饰的腺病毒载体
CA2589602A1 (en) * 2004-09-01 2006-04-13 Genvec, Inc. Adenoviral vectors able to transduce apcs, potential use in immune response generation
EP1819823A2 (en) 2004-12-01 2007-08-22 Bayer Schering Pharma Aktiengesellschaft Generation of replication competent viruses for therapeutic use
WO2007027860A2 (en) 2005-08-31 2007-03-08 Genvec, Inc. Adenoviral vector-based malaria vaccines
DE102005055128B4 (de) 2005-11-15 2015-04-02 Universität Rostock Viraler Vektor, dessen Verwendung zur Therapie von Leberzellkarzinomen und pharmazeutische Mittel umfassend den Vektor
ES2304281B1 (es) 2006-02-01 2009-08-12 Dnatrix Inc. Adenovirus oncoliticos para el tratamiento del cancer.
WO2008080003A2 (en) 2006-12-22 2008-07-03 Bayer Schering Pharma Aktiengesellschaft Generation of oncolytic adenoviruses and uses thereof
US20110086005A1 (en) 2008-05-27 2011-04-14 Oncolytics Biotech Inc. Modulating interstitial pressure and oncolytic viral delivery and distribution
CN101381742A (zh) * 2008-10-23 2009-03-11 浙江理工大学 晚期启动子靶向性调控溶瘤腺病毒pCN305载体及其构建方法与应用
ES2385251B1 (es) * 2009-05-06 2013-05-06 Fundació Privada Institut D'investigació Biomèdica De Bellvitge Adenovirus oncolíticos para el tratamiento del cáncer.
EP2486137B1 (en) * 2009-10-05 2018-05-30 Ya-Fang Mei Replication-competent ad11p based viral vectors
KR101957616B1 (ko) 2010-08-16 2019-03-12 더 솔크 인스티튜트 포 바이올로지칼 스터디즈 아데노바이러스 조립 방법
AU2011306845C1 (en) 2010-09-24 2015-05-14 Oncos Therapeutics Oy Oncolytic adenoviral vectors coding for monoclonal anti - CTLA - 4 antibodies
US20130323205A1 (en) * 2010-09-24 2013-12-05 Oncos Therapeutics Oy Oncolytic adenoviral vectors and methods and uses related thereto
US20140316369A1 (en) 2011-11-14 2014-10-23 Regenerative Sciences, Llc Suspended particle delivery systems and methods
CN102586327B (zh) 2012-01-18 2013-09-11 陕西师范大学 一步法构建携带外源基因的d24纤维蛋白修饰的条件复制型腺病毒载体及其应用
JP2016512199A (ja) 2013-03-05 2016-04-25 ベイラー カレッジ オブ メディスンＢａｙｌｏｒ Ｃｏｌｌｅｇｅ Ｏｆ Ｍｅｄｉｃｉｎｅ 腫瘍溶解性ウイルス
GB201322851D0 (en) 2013-12-23 2014-02-12 Psioxus Therapeutics Ltd Method
AU2014338864C1 (en) * 2013-10-25 2020-07-16 Akamis Bio Limited Oncolytic adenoviruses armed with heterologous genes
DK3071697T3 (da) 2013-11-22 2020-01-27 Dnatrix Inc Adenovirus der udtrykker immuncelle-stimulatorisk(e) receptor agonist(er)
GB201406608D0 (en) 2014-04-12 2014-05-28 Psioxus Therapeutics Ltd Virus
GB201510197D0 (en) * 2014-06-12 2015-07-29 Psioxus Therapeutics Ltd Method of treating ovarian cancer
GB201503500D0 (en) 2015-03-02 2015-04-15 Ucl Business Plc Cell
US11485791B2 (en) 2015-03-17 2022-11-01 Tilt Biotherapeutics Oy Oncolytic adenoviruses coding for bi-specific antibodies
US11000559B2 (en) 2015-04-30 2021-05-11 Psioxus Therapeutics Limited Oncolytic adenovirus encoding a B7 protein
MX2018007249A (es) 2015-12-17 2019-05-16 Psioxus Therapeutics Ltd Adenovirus del grupo b que codifica un anticuerpo contra el complejo tcr o fragmento de este.
AU2017233072B2 (en) 2016-03-18 2020-12-24 Nantcell, Inc. Multimodal vector for dendritic cell infection
GB201713765D0 (en) 2017-08-28 2017-10-11 Psioxus Therapeutics Ltd Modified adenovirus
CA3034517A1 (en) 2016-08-29 2018-03-08 Psioxus Therapeutics Limited Adenovirus armed with bispecific t cell activator
US20200040059A1 (en) 2016-10-20 2020-02-06 Alpine Immune Sciences, Inc. Secretable variant immunomodulatory proteins and engineered cell therapy
WO2018083259A1 (en) 2016-11-03 2018-05-11 Psioxus Therapeutics Limited Oncolytic adenovirus encoding transgenes
WO2018083257A1 (en) 2016-11-03 2018-05-11 Psioxus Therapeutics Limited Oncolytic adenovirus encoding transgenes
WO2018083258A1 (en) 2016-11-03 2018-05-11 Psioxus Therapeutics Limited Oncolytic adenovirus encoding at least three transgenes
ES2952601T3 (es) * 2017-06-01 2023-11-02 Akamis Bio Ltd Virus oncolítico y método
GB201801614D0 (en) 2018-01-31 2018-03-14 Psioxus Therapeutics Ltd Formulation

Also Published As

Publication number Publication date
JP7162929B2 (ja) 2022-10-31
KR102643574B1 (ko) 2024-03-06
CN108396015B (zh) 2022-02-18
AU2018201446B2 (en) 2020-05-28
EA201791971A1 (ru) 2018-04-30
US20170266243A1 (en) 2017-09-21
DK3288573T3 (da) 2020-03-16
IL258044A (en) 2018-05-31
IL255286B (en) 2021-01-31
CN108396015A (zh) 2018-08-14
IL258044B (en) 2021-07-29
US10849945B2 (en) 2020-12-01
EP3391892A1 (en) 2018-10-24
KR20180118249A (ko) 2018-10-30
KR20240032177A (ko) 2024-03-08
US20210338753A1 (en) 2021-11-04
US10548929B2 (en) 2020-02-04
SA520412637B1 (ar) 2022-03-01
AU2016256582B2 (en) 2020-10-29
ZA201801589B (en) 2019-10-30
US11000559B2 (en) 2021-05-11
PE20180241A1 (es) 2018-01-31
PE20181140A1 (es) 2018-07-17
JP6931229B2 (ja) 2021-09-01
PT3288573T (pt) 2020-03-25
CL2017002731A1 (es) 2018-06-08
US20180140649A1 (en) 2018-05-24
ES2780366T3 (es) 2020-08-25
AU2016256582A1 (en) 2017-11-16
US20190076493A1 (en) 2019-03-14
PH12017501942A1 (en) 2018-03-19
US20170056458A1 (en) 2017-03-02
PL3288573T3 (pl) 2020-05-18
JP2018139586A (ja) 2018-09-13
AU2016256582A8 (en) 2018-01-18
KR20180022638A (ko) 2018-03-06
JP2021176339A (ja) 2021-11-11
HK1249009A1 (zh) 2018-10-26
US10322152B2 (en) 2019-06-18
CY1122833T1 (el) 2021-05-05
CO2017010831A2 (es) 2018-02-28
CN107690479A (zh) 2018-02-13
IL284375A (en) 2021-07-29
US10124028B2 (en) 2018-11-13
EP3288573B1 (en) 2020-02-12
HRP20200439T1 (hr) 2020-06-12
JP6928380B2 (ja) 2021-09-01
IL255286A0 (en) 2017-12-31
BR122018004815A2 (pt) 2019-09-10
EA037611B1 (ru) 2021-04-21
RS60105B1 (sr) 2020-05-29
MX2017013684A (es) 2018-08-28
SG10201803081TA (en) 2018-06-28
LT3288573T (lt) 2020-03-25
SG10201901482XA (en) 2019-03-28
WO2016174200A1 (en) 2016-11-03
MY183703A (en) 2021-03-09
SA517390260B1 (ar) 2021-11-10
CA2984038C (en) 2023-01-03
AU2020223665A1 (en) 2020-09-10
CA2984038A1 (en) 2016-11-03
SI3288573T1 (sl) 2020-06-30
EP3288573A1 (en) 2018-03-07
CN107690479B (zh) 2022-02-18
US20180042973A1 (en) 2018-02-15
SG11201708604TA (en) 2017-11-29
HUE048320T2 (hu) 2020-07-28
JP2018514199A (ja) 2018-06-07
IL284375B (en) 2022-07-01
AU2018201446A1 (en) 2018-03-29
CL2018000587A1 (es) 2018-08-10

Similar Documents

Publication Publication Date Title
BR112017023171A2 (pt) adenovírus oncolítico que codifica proteína b7
BR112018012179A2 (pt) adenovírus de grupo b que codifica um anticorpo ou fragmento de complexo anti-tcr
BR112019001737A2 (pt) expressão de pten-long com vírus oncolíticos
CY1123385T1 (el) Υψηλης συγγενειας pd-1 παραγοντες και μεθοδοι χρησης
BR112018008766A2 (pt) variantes, composições e métodos e utilizações do fator viii reduzido cpg para o tratamento de transtornos hemostásicos
BR112018011711A2 (pt) peptídeos de direcionamento para direcionar virus adeno-associados (aav)
CY1123419T1 (el) Αντιδραστηρια sirp-αλφα υψηλης συγγενειας
BR112018071584A2 (pt) métodos para modular de maneira seletiva a ativida-de de subtipos distintos de células
CO2017009954A2 (es) Dominios diseñados con repeticiones de anquirina con especificidad de unión para la seroalbúmina
BR112017014917A2 (pt) elementos regulatórios pós-transcricionais modificados de hepatite
BR112018071200A2 (pt) terapia genética para o tratamento da hemofilia a
BR112017017884A2 (pt) switches transcricionais desencadeados por ligação e métodos de uso dos mesmos
MX2021001158A (es) Vector hsv oncolitico.
EP4043021A3 (en) Oncolytic tumor viruses and methods of use
BR112019002646A2 (pt) composições de poxvírus quimérico e usos das mesmas
BR112019010275A2 (pt) adenovírus recombinante, composição, uso do adenovírus ou composição, método de induzir uma resposta imune em um paciente, e, adenovírus de símio não humano
BRPI0909285A2 (pt) promotor, elementos de controle do promotor, e combinações e usos dos mesmos
BR112021024127A2 (pt) Adenovírus modificado
BR112018073238A2 (pt) vírus oncolíticos compreendendo esrage e métodos de tratamento de câncer
BR112018075692A2 (pt) genes cln1 otimizados e cassetes de expressão e seu uso
BR112019024656A2 (pt) vírus oncolíticos para a sensibilização de células tumorais para morte por células exterminadoras naturais
AR113134A1 (es) Arni variante
BR112017002549A2 (pt) mutações em proteínas de grupos de ferro e enxofre que aperfeiçoam a utilização de xilose
WO2018060368A3 (en) COMPOSITIONS AND METHODS FOR ENHANCING STABILITY OF TRANSGENES IN POXVIRUSES
BR112021025031A2 (pt) Terapia de combinação de adenovírus oncolítico e inibidor de checkpoint

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]

Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS.

B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B25D Requested change of name of applicant approved

Owner name: AKAMIS BIO LIMITED (GB)

B25G Requested change of headquarter approved

Owner name: AKAMIS BIO LIMITED (GB)

B06G Technical and formal requirements: other requirements [chapter 6.7 patent gazette]